Differences

This shows you the differences between two versions of the page.

--- covid-19_pandemic:research_retractions [2022/01/05 06:29]
pri [Vaccine Research Retractions]
+++ covid-19_pandemic:research_retractions [2022/01/11 21:12] (current)
robin [Early Treatment Medicine Retractions]
@@ Line 11: / Line 11: @@
 On June 5, 2020, the paper was retracted by Lancet and the authors, as was another published in the New England Journal of Medicine that found that the use of ACE-2 inhibitors did not increase risk of COVID hospital-deaths.  The WHO reinstated the Solidarity HCQ trial following the retraction, and then officially halted it on June 19, 2020.
+After the Lancet paper was retracted, on June 18, 2020 another paper was published in the New England Journal of Medicine by three of the same authors of the Lancet study and two others (Mandeep R. Mehra, M.D., Sapan S. Desai, M.D., Ph.D., SreyRam Kuy, M.D., M.H.S., Timothy D. Henry, M.D., and Amit N. Patel, M.D.). The study, [[https://www.nejm.org/doi/full/10.1056/NEJMoa2007621?query=recirc_curatedRelated_article|Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19]], relied on the data from the Surgisphere data set.  The conclusions of this study countered previous findings of a potential harmful association of ACE inhibitors or ARBs with in-hospital CoVid-19 deaths.
+This second study using Surgisphere data was [[https://www.nejm.org/doi/full/10.1056/NEJMc2021225|retracted]] by the authors on June 25, 2020, just one week following its publication.  The retraction reads:  "Because all the authors were not granted access to the raw data and the raw data could not be made available to a third-party auditor, we are unable to validate the primary data sources underlying our article, “Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.”1 We therefore request that the article be retracted. We apologize to the editors and to readers of the Journal for the difficulties that this has caused."